Metanib 400 mg (Tablet)
Unit Price: ৳ 250.00 (4 x 7: ৳ 7,000.00)
Strip Price: ৳ 1,750.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Imatinib mesylate |
| Company | Drug international ltd |
Indications
- Treatment for Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML)
- Treatment for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
- Treatment for myelodysplastic/myeloproliferative diseases
- Treatment for aggressive systemic mastocytosis
- Treatment for hypereosinophilic syndrome and/or chronic eosinophilic leukemia
- Treatment for dermatofibrosarcoma protuberans
- Treatment for unresectable and/or metastatic gastrointestinal stromal tumors
- Adjuvant treatment following complete gross resection of gastrointestinal stromal tumors
Pharmacology
- Protein-tyrosine kinase inhibitor
- Inhibits Bcr-Abl tyrosine kinase (TK)
- Inhibits receptor tyrosine kinases: Kit, DDR1, DDR2, CSF-1R, PDGFR-alpha, PDGFR-beta
- Well-absorbed after oral administration
- Mean absolute bioavailability of 98%
- Metabolized by CYP3A4
- Predominantly eliminated in the feces
Dosage and administration
- Adults with Ph+ CML CP: 400 mg/day
- Adults with Ph+ CML AP or BC: 600 mg/day
- Pediatrics with Ph+ CML CP: 340 mg/m2/day
- Doses should be taken with a meal and a large glass of water
- Dose of 800 mg should be administered as 400 mg twice a day
- Can be dissolved in water or apple juice for patients having difficulty swallowing
Interaction
- Concomitant administration with strong CYP3A4 inducers may reduce total exposure
- Concomitant administration with strong CYP3A4 inhibitors may result in significant exposure increase
- May increase plasma concentration of CYP3A4 metabolized drugs
- Use caution when administering with CYP2D6 substrates
Side effects
- Fluid retention and edema
- Hematologic toxicity
- Congestive heart failure and left ventricular dysfunction
- Hepatotoxicity
- Hemorrhage
- Gastrointestinal disorders
- Dermatologic toxicities
- Hypothyroidism
- Growth retardation in children and adolescents
- Tumor lysis syndrome
- Impairments related to driving and using machinery
- Renal toxicity
Pregnancy and lactation
- Effective contraception advised during treatment
- Limited data on use in pregnant women
- Potential reproductive toxicity in animals
- Distributed into human milk
- Unknown effects of low-dose exposure on infants
- Effect on fertility and gametogenesis not fully studied
Precautions and warnings
- Severe fluid retention and edema
- Cytopenias, particularly anemia, neutropenia, and thrombocytopenia
- Severe congestive heart failure and left ventricular dysfunction
- Severe hepatotoxicity, including fatalities
- Grade 3/4 hemorrhage
- Bullous dermatologic reactions
- Fetal harm
- Growth retardation in children and pre-adolescents
- Tumor lysis syndrome
- Renal toxicity
Overdose effects
- Nausea, vomiting, diarrhea
- Rash, erythema, edema, swelling
- Fatigue, muscle spasms
- Thrombocytopenia, pancytopenia
- Abdominal pain, headache
- Weakness, myalgia
- Increased creatine phosphokinase, bilirubin
- Gastrointestinal pain
Therapeutic class
- Targeted Cancer Therapy
- Tyrosine Kinase Inhibitor
Storage conditions
- Store below 30°C
- Cool and dry place
- Keep away from light
- Keep out of the reach of children